GBT GLOBAL BLOOD THERAPEUTICS, INC. gains 16% Nov 10, 2017

Posted By: Rajesh Srivastava - Friday, November 10, 2017

Share

& Comment

Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics to treat grievous blood-based disorders. Its product candidate is GBT440, a hemoglobin modifier that binds to hemoglobin molecules, which is in double-blind Phase I/II clinical trial indicated for the treatment of sickle cell disease. The company also focuses on developing an oral prophylactic therapy for hypoxemic pulmonary disorders and hereditary angioedema. The company was founded in 2011 and is headquartered in South San Francisco, California. http://www.priceseries.com/trade/GBT-GLOBAL-BLOOD-THERAPEUTICS-INC-stock-gains-16-percent-a-Trade-Record-by-priceSeries-2017102420171110.html

About Rajesh Srivastava

Techism is an online Publication that complies Bizarre, Odd, Strange, Out of box facts about the stuff going around in the world which you may find hard to believe and understand. The Main Purpose of this site is to bring reality with a taste of entertainment

0 comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Copyright © priceSeries Daily Results™ is a registered trademark.

Designed by Templateism. Hosted on Blogger Platform.